Division of Evolution, Infection and Genomics, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK.
National Aspergillosis Centre, Department of Infectious Diseases, Manchester University NHS Foundation Trust, Manchester, UK.
Mycoses. 2023 Nov;66(11):960-968. doi: 10.1111/myc.13641. Epub 2023 Aug 8.
Chronic pulmonary aspergillosis (CPA) is associated with significant mortality, and suboptimal antifungal treatment response. We describe predictive factors for treatment response and survival.
We retrospectively analysed clinical, serological and radiological parameters at baseline and following antifungal treatment in patients with CPA and correlated with clinical and radiological response and survival.
Fifty-nine patients were included with a mean age of 61 years. Thirty (51%) had a diagnosis of COPD. On clinical assessment at 6 months, 21 (36%) had clinically improved, 20 (34%) were clinically stable and 15 (25%) had deteriorated. Radiological improvement was observed in 30 (53%), stability in 11 (19%) and deterioration in 16 (28%). Only a lower C-reactive protein (CRP) at baseline was associated with a favourable clinical-radiological response. On univariate analysis, lower CRP, higher albumin, lower Aspergillus IgG and use of inhaled steroids were associated with lower mortality. An overall favourable response at 6 months was associated with lower mortality.
Inflammatory markers and Aspergillus IgG were predictors of mortality in CPA. This suggests that mortality in CPA is driven mainly by the chronic fungal infection itself rather than the underlying disease, therefore early optimised treatment of CPA may lead to improved outcomes.
慢性肺曲霉病(CPA)与高死亡率和抗真菌治疗反应不理想相关。我们描述了治疗反应和生存的预测因素。
我们回顾性分析了 CPA 患者基线时和抗真菌治疗后的临床、血清学和影像学参数,并与临床和影像学反应及生存相关联。
共纳入 59 例患者,平均年龄 61 岁。30 例(51%)有 COPD 诊断。6 个月时临床评估,21 例(36%)临床改善,20 例(34%)临床稳定,15 例(25%)恶化。30 例(53%)影像学改善,11 例(19%)稳定,16 例(28%)恶化。只有基线时较低的 C 反应蛋白(CRP)与良好的临床-影像学反应相关。单因素分析显示,较低的 CRP、较高的白蛋白、较低的曲霉 IgG 和使用吸入性类固醇与较低的死亡率相关。6 个月时总体良好的反应与较低的死亡率相关。
炎症标志物和曲霉 IgG 是 CPA 患者死亡率的预测因素。这表明,CPA 中的死亡率主要由慢性真菌感染本身驱动,而不是由潜在疾病驱动,因此早期优化治疗 CPA 可能会带来更好的结果。